Daré Bioscience (DARE) posts updated corporate investor presentation

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Daré Bioscience, Inc. furnished an updated corporate presentation on April 22, 2026. The presentation was made available in the Investors section of the company’s website and attached as Exhibit 99.1 to this report.

The information in Item 7.01 and Exhibit 99.1 is provided under Regulation FD and is expressly stated as furnished, not filed, meaning it is not subject to certain Exchange Act liability provisions and is not automatically incorporated into other Securities Act or Exchange Act filings.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Terms

Regulation FD Disclosure, furnished and shall not be deemed to be filed, incorporated by reference

3 terms

Regulation FD Disclosure regulatory

"Item 7.01 Regulation FD Disclosure. On April 22, 2026, Daré Bioscience, Inc."

Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.

furnished and shall not be deemed to be filed regulatory

"The information in this Item 7.01 and Exhibit 99.1 to this report is being furnished and shall not be deemed to be “filed”"

incorporated by reference regulatory

"nor shall such information be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933"

Understanding 8-K Material Events →

04/22/2026 - 09:00 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 22, 2026

DARÉ BIOSCIENCE, INC.

Dare Bioscience, Inc

(Exact name of registrant as specified in its charter)

Delaware

001-36395

20-4139823

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

3655 Nobel Drive, Suite 260

San Diego, CA 92122

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (858) 926-7655

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock		DARE		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On April 22, 2026, Daré Bioscience, Inc. (“Daré” or the “Company”) made available an updated corporate presentation in the “Investors” section of its website (https://ir.darebioscience.com). A copy of the presentation, dated April 22, 2026, is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

The information in this Item 7.01 and Exhibit 99.1 to this report is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation by reference language in any such filing, except as the Company expressly sets forth by specific reference in such filing.

Information contained in, or that can be accessed through, the Company’s website or any other website referenced in its corporate presentation is not incorporated by reference into this report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Daré Bioscience corporate presentation, dated April 22, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	DARÉ BIOSCIENCE, INC.

Dated: April 22, 2026	By:	/s/ Sabrina Martucci Johnson
	Name:	Sabrina Martucci Johnson
	Title:	President and Chief Executive Officer

-3-

Exhibit 99.1

Source: View Original Filing on SEC EDGAR

FAQ

What did Daré Bioscience (DARE) disclose in its April 22, 2026 8-K?

Daré Bioscience disclosed that it made an updated corporate presentation available on its website on April 22, 2026. The presentation is attached as Exhibit 99.1 to the report and is provided as Regulation FD disclosure.

Where can investors find Daré Bioscience’s updated April 22, 2026 corporate presentation?

Investors can access Daré Bioscience’s updated corporate presentation in the Investors section of its website at https://ir.darebioscience.com. The same presentation is also furnished as Exhibit 99.1 to the April 22, 2026 current report.

Is Daré Bioscience’s April 22, 2026 corporate presentation considered filed with the SEC?

No. The company states that the information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act. This means it is not subject to Section 18 liabilities and is not automatically incorporated into other SEC filings.

What exhibit did Daré Bioscience attach to its April 22, 2026 8-K?

Daré Bioscience attached its corporate presentation dated April 22, 2026 as Exhibit 99.1. The company also included Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document, as part of the submission.

Does the Daré Bioscience (DARE) website information become part of this 8-K?

No. The company specifies that information contained in, or accessible through, its website or other websites referenced in the corporate presentation is not incorporated by reference into this report, limiting the report strictly to the furnished exhibits.

Filing Exhibits & Attachments

40 documents